Clinical observation on combined buprenorphine transdermal patch and gabapentin in the treatment of diabetic peripheral neuralgia
10.3760/cma.j.issn.1008-1372.2015.10.007
- VernacularTitle:加巴喷丁联合小剂量丁丙诺菲透皮贴治疗糖尿病周围神经痛的临床观察
- Author:
Ying HE
;
Chengfu WAN
;
Tao SONG
- Publication Type:Journal Article
- Keywords:
Gamma-aminobutyric acid/AA/AD;
Buprenorphine/AD;
Diabetic neuropathies/DT
- From:
Journal of Chinese Physician
2015;17(10):1465-1467
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the effect of buprenorphine transdermal patch combined with gabapentin in patients with diabetic peripheral neuralgia (DPN).Methods Sixty patients were divided randomly into experimental (A) and control (B) groups.Patients in group A were treated with buprenorphine transdermal patch combined gabapentin.Patients in group B were orally administered pregabalin only.The period of treatment was 8 weeks.The analgesic effect [visual analogue scale (VAS) scores] , sleep scores, daily doses of gabapentin, and adverse reactions were evaluated before treatment, and the 2nd weeks, 4th weeks and 8th weeks after treatment.Results The VAS scores of group A were significantly lower than group B at 4th weeks and 8th weeks after treatment [(2.8 ± 1.6) points vs (3.8 ± 1.5) points,(2.6 ± 0.5) points vs (3.5 ± 1.6) points, P ＜ 0.05].The sleep scores of group A were significantly higher than group B (P ＜ 0.01).The daily doses of gabapentin were significantly lower [(853.0 ± 349.8) mg vs (1575.8 ± 351.0) mg, (845.1 ± 342.7) mg vs (1434.2 ± 440.8) mg, (826.9 ± 298.5) mg vs (1389.8 ±356.6)mg, P ＜ 0.05].The incidence of adverse reactions was significantly lower in group A (10.7％ vs 25.9％ , 10.7％ vs 29.6％ , P ＜ 0.05).Conclusions The combination of buprenorphine transdermal patch and gabapentin is effective and safe for the patients with DPN.
